Search results
Benefits of Spironolactone: Win Ratio Analysis of the TOPCAT Trial
Author(s):
Dung Viet Nguyen
,
Hoai Thi Thu Nguyen
Added:
6 months ago
Original Research
COVID-19 and Cardiovascular Care in Asia-Pacific
Author(s):
Mitsuaki Sawano
,
Misato Chimura
,
Jonathan Yap
,
et al
Added:
1 year ago
Original Research
New Horizons in Cardiomyopathy 2025
Video Series
Added:
7 months ago
Source:
Radcliffe Cardiology
Treatment with volenrelaxin, a long-acting human relaxin analogue, was associated with worsening congestion in patients with recently decompensated heart failure with preserved ejection fraction (HFpEF), leading to the early termination of the phase 2 RELAXIN-LA trial.¹ Despite this, the lowest dose of the drug did show an improvement in the study's primary endpoint.Relaxin is a peptide hormone…
View more
Author(s):
Harriette Van Spall
,
Stefan James
Added:
1 year ago
What's hot at the ESC Congress 2024?Stay ahead of the curve with our faculty-led coverage of the European Society of Cardiology Congress in London. From groundbreaking trials to expert insights, we've got you covered.Watch ourView From the Thoraxcenterseries for practice-focused reviews of the most anticipated trials from interventional experts,Prof Nicolas Van MieghemandDr Joost Daemen.For a…
View more
Author(s):
Erwan Donal
Added:
1 week ago
ACC 2026 - Two randomised trials position TriClip TEER as a transformative option in TR, delivering significant reductions in heart failure hospitalisations and supporting earlier intervention in clinical practice.Prof Erwan Donal (Hospital Pontchaillou of Rennes, Rennes, FR) joins us on-site at ACC 2026 to share the findings from two randomised trials (Tri.Fr and TRILUMINATE Pivotal)…
View more
Author(s):
Akshay S Desai
Added:
1 year ago
HFSA 24 - Dr Akshay Desai (Brigham and Women’s Hospital, US) sits down with us to discuss the findings from FINEARTS-HF across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction.Interview Questions:1. What was the reasoning behind this study? What was the study design and patient population?2. What was the study design and patient population?3…
View more
Francis D Pagani
Author
Author(s):
Biykem Bozkurt, Pardeep Jhund, Muthiah Vaduganathan
Start date:
Sep 11, 2024
Join us for an unparalleled educational journey dedicated to tackling the complexities of managing HFpEF and HFmrEF patients. This CME-accredited live roundtable is chaired by Dr Biykem Bozkurt (Baylor College of Medicine, US) and features insights from renowned experts Prof Pardeep Jhund (University of Glasgow, UK) and Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical…
View more